Calistoga Pharmaceuticals have initiated a Phase I trial with PI3K inhibitor CAL-101. The trial will be carried out in patients with chronic lymphocytic leukemia
Filed under: kinase | Tagged: CAL-101, CAL101, Calistoga, phase I, PI3K | Comments Off
Calistoga initiate Phase I trial with PI3K delta inhibitor CAL-101
Posted on July 10, 2008 by crimsoncanary
Welichems WBI-1001 successfully completes Phase I trial
Posted on July 10, 2008 by crimsoncanary
Welichem Biotech’s topical lck/ck2 kinase inhibitor WBI-1001 has completed a Phase I trial in psoriasis patients. The drug demonstrated an excellent non-cutaneous safety profile.
Filed under: Uncategorized | Tagged: ck2, kinase, lck, phase I, psoriasis, WBI-1001, WBI1001, Welichem, Welichem Biotech | Comments Off
